Crispr Therapeutics AG vs Taskus Inc — how do they compare? Crispr Therapeutics AG trades at $50.71 (market cap $4.99B), while Taskus Inc trades at $5.61 (market cap $514.67M). The key difference: Crispr Therapeutics AG is far larger — about 9.7× Taskus Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | TASK | |
|---|---|---|
Market Cap | $4.99B | $514.67M |
Sector | Health | Technology |
52-Week High | $76.78 | $18.21 |
52-Week Low | $44.34 | $4.57 |
Enterprise Value | $3.33B | $910.37M |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →